Latest STOPCAP results presented at APCCC 2026

30 April – 2 May 2026

Room B12, First Floor, Convention Centre

Peter Godolphin and David Fisher will be attending the Advanced Prostate Cancer Consensus Conference (APCCC) 2026 in Lugano.  They will both be presenting posters of updated STOPCAP individual participant data (IPD) meta-analyses.  Peter will be presenting new results of the effects of prostate RT on mHSPC, first presented at ESMO 2025.  David will be presenting new results of the effects of ARPI’s on mHSPC, first presented at GU ASCO 2025.

Results from both of these STOPCAP projects are being prepared for full publication.

 

Poster 14

Which patients with synchronous, metastatic hormone-sensitive prostate cancer benefit from prostate radiotherapy? STOPCAP meta-analysis of individual participant data

S Burdett¹*, PJ Godolphin¹*, A Sachdeva², LR Murphy¹, LH Rydzewska¹, DJ Fisher¹, S Foulon³, LM Boevé⁴, CC Parker⁵, A Bossi⁶, G van Andel⁴, G Attard⁷, K Chi⁸, NW Clarke⁹, K Fizazi¹⁰, S Gillessen¹¹, ND James¹², D Matheson¹³, RE Oldroyd¹⁴, MKB Parmar^1,15, CJ Sweeney¹⁶, B Tombal¹⁷, IR White^1,15, JF Tierney¹. *Equal contribution

¹ UCL Innovative Clinical Trials Unit (formerly MRC Clinical Trials Unit at UCL), UCL, UK; ² Division of Cancer Sciences, The University of Manchester, UK; ³ Biostatistics and Epidemiology, Gustave Roussy, FR; ⁴ Dept of Urology, OLVG, NL; ⁵ Dept of Urology, The Royal Marsden Hospital, UK;  ⁶ Radiotherapy Dept, Gustave Roussy, FR; ⁷ Research Dept of Oncology, UCL, UK; ⁸ BC Cancer-Vancouver Cancer Center, CA; ⁹ Urology Dept, The Christie NHS Foundation Trust, UK; ¹⁰ Cancer Medicine Dept, Gustave Roussy, FR; ¹¹ Medical Oncology Dept, CH; ¹² Prostate and Bladder Cancer Research Dept, Institute of Cancer Research, UK; ¹³ Faculty of Education, University of Wolverhampton, UK; ¹⁴ PPI Partner, UK; ¹⁵ MRC Centre of Research Excellence in Clinical Trial Innovation, UCL, UK; ¹⁶ South Australian Immunogenomics Cancer Institute, The University of Adelaide, AU; ¹⁷ Urology Dept, Cliniques Universitaires Saint-Luc, BE.

 

Poster 15

Which people with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP individual participant data meta-analysis

DJ Fisher¹, LH Rydzewska¹, PJ Godolphin¹, CL Vale¹, N Agarwal², G Attard³, KN Chi⁴, N Clarke⁵, ID Davis⁶, K Fizazi⁷, S Gillessen^8,9, ND James¹⁰, D Matheson¹¹, R Oldroyd¹, MKB Parmar^1,12, C Sweeney¹³, BF Tombal¹⁴, IR White^1,12, JF Tierney¹

¹ UCL Innovative Clinical Trials Unit (formerly MRC Clinical Trials Unit at UCL), London, UK; ² Huntsman Cancer Institute, Salt Lake City, UT; ³ University College London Cancer Institute, London, UK; ⁴ University of British Columbia, BC Cancer-Vancouver Cancer Center, Vancouver, BC; ⁵ The Christie and Salford Royal Hospital NHS Foundation Trusts, Manchester, UK; ⁶ Monash University and Eastern Health, Box Hill, Australia; ⁷ Centre Oscar Lambret, Lille, France; ⁸ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; ⁹ Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland; ¹⁰ The Royal Marsden Hospital NHS Foundation Trust, London, UK; ¹¹ University of Wolverhampton, Walsall, UK; ¹² MRC Centre of Research Excellence in Clinical Trial Innovation, UCL, UK; ¹³ South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia; ¹⁴Cliniques Universitaires Saint-Luc, Brussels, Belgium